These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34125796)

  • 1. SGLT2 inhibitors: A revolution in therapeutics of a Major Non-Communicable Disease.
    Khan MS
    J Pak Med Assoc; 2021 Apr; 71(4):1293. PubMed ID: 34125796
    [No Abstract]   [Full Text] [Related]  

  • 2. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
    Cruz JE; Ahuja T; Bridgeman MB
    Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT2 inhibitors for primary prevention of cardiovascular events.
    Raz I; Cernea S; Cahn A
    J Diabetes; 2020 Jan; 12(1):5-7. PubMed ID: 31755238
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison chart: SGLT2 inhibitors.
    Med Lett Drugs Ther; 2020 Nov; 62(1611):e2-e4. PubMed ID: 33429417
    [No Abstract]   [Full Text] [Related]  

  • 5. Considerations for SGLT2 inhibitor use in post-transplantation diabetes.
    Hecking M; Jenssen T
    Nat Rev Nephrol; 2019 Sep; 15(9):525-526. PubMed ID: 31235880
    [No Abstract]   [Full Text] [Related]  

  • 6. SGLT2 Inhibitors: The Dawn of a New Era in Cardio-Metabolic Therapeutics.
    Deedwania P
    Am J Cardiovasc Drugs; 2022 Jan; 22(1):1-4. PubMed ID: 34458960
    [No Abstract]   [Full Text] [Related]  

  • 7. Does Metformin Interfere With the Cardiovascular Benefits of SGLT2 Inhibitors? Questions About Its Role as the Cornerstone of Diabetes Treatment.
    Packer M
    Am J Med; 2020 Jul; 133(7):781-782. PubMed ID: 32061625
    [No Abstract]   [Full Text] [Related]  

  • 8. Diabetic nephropathy: Renoprotective effects of GLP1R agonists and SGLT2 inhibitors.
    Hocher B; Tsuprykov O
    Nat Rev Nephrol; 2017 Dec; 13(12):728-730. PubMed ID: 28989173
    [No Abstract]   [Full Text] [Related]  

  • 9. Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?
    Packer M
    Am J Med; 2018 May; 131(5):461-463. PubMed ID: 29309741
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A protocol for systematic review and meta-analysis.
    Yu B; Dong C; Hu Z; Liu B
    Medicine (Baltimore); 2021 Feb; 100(8):e24655. PubMed ID: 33663074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors.
    Kuchay MS; Farooqui KJ; Mishra SK; Mithal A
    Adv Exp Med Biol; 2021; 1307():213-230. PubMed ID: 32006266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium-glucose co-transporter-2 inhibitors with those receiving dipeptidyl peptidase-4 inhibitors, using a supervised machine-learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database.
    Zhou FL; Watada H; Tajima Y; Berthelot M; Kang D; Esnault C; Shuto Y; Maegawa H; Koya D
    Diabetes Obes Metab; 2019 Aug; 21(8):1925-1934. PubMed ID: 31050099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus.
    Fattah H; Vallon V
    Drugs; 2018 May; 78(7):717-726. PubMed ID: 29663292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent progress of sodium-glucose transporter 2 inhibitors as potential antidiabetic agents.
    Zhang Y; Ban H; Yu R; Wang Z; Zhang D
    Future Med Chem; 2018 May; 10(10):1261-1276. PubMed ID: 29749749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Turning Foes to Friends: Knocking Down Diabetes Associated SGLT2 Transporters and Sustaining Life.
    Gupta A; Mittal S; Monika ; Dhingra R; Dhingra N
    Curr Diabetes Rev; 2020; 16(7):716-732. PubMed ID: 31951170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetes mellitus: Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS.
    Vallon V; Thomson SC
    Nat Rev Nephrol; 2017 Sep; 13(9):517-518. PubMed ID: 28781373
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of sodium-glucose cotransporter 2 inhibitors in older patients with type 2 diabetes mellitus.
    Kambara T; Shibata R; Osanai H; Nakashima Y; Asano H; Sakai K; Murohara T; Ajioka M
    Geriatr Gerontol Int; 2018 Jan; 18(1):108-114. PubMed ID: 28861952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical considerations when adding a sodium-glucose co-transporter-2 inhibitor to insulin therapy in patients with diabetes mellitus.
    Tan K; Chow WS; Leung J; Ho A; Ozaki R; Kam G; Li J; Choi CH; Tsang MW; Chan N; Lee KK; Chan KW
    Hong Kong Med J; 2019 Aug; 25(4):312-319. PubMed ID: 31416990
    [No Abstract]   [Full Text] [Related]  

  • 19. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.
    Med Lett Drugs Ther; 2019 Feb; 61(1566):26-28. PubMed ID: 30845101
    [No Abstract]   [Full Text] [Related]  

  • 20. Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms.
    Bajaj HS; Zinman B
    Physiology (Bethesda); 2018 May; 33(3):197-210. PubMed ID: 29638185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.